ライフサイエンスコーパス: triamcinolone

1 ns-scleral delivery of posterior sub-Tenon's triamcinolone.

2 the most common complications of intraocular triamcinolone.

3 examethasone or intravitreal/subconjunctival triamcinolone.

4 ook both colchicine (0.6 mg/twice a day) and triamcinolone.

5 ema responded to intravitreal treatment with triamcinolone.

6 id responsiveness testing with intramuscular triamcinolone.

7 6 weeks of successful treatment with topical triamcinolone.

8 per QALY compared with laser treatment plus triamcinolone.

9 ated successfully with a second injection of triamcinolone.

10 Ten eyes received mitomycin C (MMC) and triamcinolone.

11 ontaminated, compounded combined bevacizumab-triamcinolone.

12 The patient was treated with intravitreal triamcinolone (0.1 mL/4 mg).

13 400 mg/kg) and an intramuscular injection of triamcinolone (0.8 mg/kg) 1 d before talc instillation a

14 hasone intravitreal implant (2 citations) or triamcinolone (1 citation), although cataract and glauco

15 , intravitreal bevacizumab (5), intravitreal triamcinolone (2), intravitreal dexamethasone implant (1

16 t with clobetasol ointment and intralesional triamcinolone; 2 patients also underwent open superficia

17 jection + prompt laser; or (4) intravitreous triamcinolone (4 mg) + prompt laser.

18 ined intravitreal corticosteroids, including triamcinolone (4) and the dexamethasone implant (2).

19 e patients received a mixture of 1 mL of the triamcinolone, 40 mg/mL, and 1 mL of 0.5% bupivacaine hy

20 week run-in period of treatment with inhaled triamcinolone (400 microg twice per day).

21 ed-release dexamethasone-5-FU device and the triamcinolone-5-FU suspension effectively inhibit the pr

22 ells (HTM) treated with dexamethasone (DEX), triamcinolone acetate, and prednisolone acetate by TaqMa

23 bone loss and who were treated with inhaled triamcinolone acetonide (100 microg per puff).

24 viability of ARPE-19 cells after exposure to triamcinolone acetonide (200 microg/mL) alone without th

25 The R28 cells exposed to triamcinolone acetonide (200 microg/mL) without the vehi

26 intervention: Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevaci

27 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevaci

28 week run-in period of treatment with inhaled triamcinolone acetonide (400 microg twice per day).

29 d with the chaperones in the presence of [3H]triamcinolone acetonide ([3H]TA), which binds to the rec

30 l retinal thickness (CRT) after intravitreal triamcinolone acetonide (IVT) injection for macular edem

31 Intravitreal triamcinolone acetonide (IVTA) is an effective treatment

32 usion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing

33 In 3 eyes, intravitreal triamcinolone acetonide (IVTA) was injected within 8 wee

34 tocol, and swollen joints were injected with triamcinolone acetonide (maximum dosage 80 mg per month)

35 ceived an average of 1.6 posterior sub-Tenon triamcinolone acetonide (PSTA) injections in the 12 mont

36 aoperative subconjunctival injection of 2 mg triamcinolone acetonide (TA) alone.

37 GR in complex with the potent glucocorticoid triamcinolone acetonide (TA) and a fragment of the small

38 culation on transscleral drug delivery using triamcinolone acetonide (TA) as a model drug.

39 racterize the safety and pharmacodynamics of triamcinolone acetonide (TA) delivered by this technique

40 ion of MR and GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transa

41 A novel conjugate of mitomycin C (MMC) and triamcinolone acetonide (TA) was synthesized using gluta

42 ating agents dexamethasone (Dex), IL-10, and triamcinolone acetonide (TA) were used to antagonize pro

43 Three agents-prednisolone acetate (PA), triamcinolone acetonide (TA), and lipid-based artificial

44 ty guidelines) and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors

45 treated with 100 microM CoCl(2), 1 microg/mL triamcinolone acetonide (TA), or both.

46 oid receptor (GR) and c-jun transcription in triamcinolone acetonide (TA)-treated AtT-20 cells.

47 The inherent electron-capture properties of triamcinolone acetonide (TAA) fatty acid conjugates were

48 Triamcinolone acetonide (TAA) is an anti-inflammatory st

49 Intra-articular administered triamcinolone acetonide (TAA) is one of the drug treatme

50 , M: 770 microg, H: 1,540 microg per day and triamcinolone acetonide (TAA) L: 400 microg, M: 800 micr

51 properties of the C21 acetate derivative of triamcinolone acetonide (TAA) under methane chemical ion

52 ed this method to quantify the low levels of triamcinolone acetonide (TACA) in porcine plasma followi

53 formulations encapsulating the model steroid triamcinolone acetonide (Tr-A) were implanted subcutaneo

54 rong cytochrome P-450 3A (CYP3A) inducer] or triamcinolone acetonide (weak CYP3A inducer) produced do

55 CT-guided TMJ injections of corticosteroid (triamcinolone acetonide [n = 16] or triamcinolone hexace

56 aser may be more effective than intravitreal triamcinolone acetonide alone.

57 ization was improved in 15 patients by using triamcinolone acetonide and in the remaining 15 patients

58 (GCs) dexamethasone, mometasone furoate, and triamcinolone acetonide are pharmaceutical mainstays to

59 corticosteroids; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cro

60 The effects of triamcinolone acetonide cream 0.025% were assessed based

61 This study compared computer-modeled triamcinolone acetonide diffusion after posterior sub-Te

62 Treatment with topical triamcinolone acetonide dramatically reduced pathology b

63 hma receiving beclomethasone dipropionate or triamcinolone acetonide during a 2-wk, single-blind, run

64 cts of intra-articular injection of 40 mg of triamcinolone acetonide every 3 months on progression of

65 Intravitreal triamcinolone acetonide followed by laser may be more ef

66 tained-release suspension releasing 5-FU and triamcinolone acetonide for 1 month.

67 50, 100, and 200 microg/mL concentration of triamcinolone acetonide for 2, 6, and 24 hours.

68 retical model predicts efficient delivery of triamcinolone acetonide from the posterior sub-Tenon's s

69 In the triamcinolone acetonide group, 12 months after surgery t

70 th intravitreal injections of bevacizumab or triamcinolone acetonide in patients with macular edema a

71 hanges following suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA),

72 Intraoperative intravitreal triamcinolone acetonide injection induces earlier and ma

73 Intravitreal triamcinolone acetonide injection therapy, in particular

74 , 3 days, and 1, 2, 3, 4, and 8 weeks) after triamcinolone acetonide injection, with 6 controls witho

75 received bevacizumab injections, 35 (44.9%) triamcinolone acetonide injections, and 5 (6.4%) a dexam

76 Triamcinolone acetonide is toxic to proliferating cells

77 n after posterior sub-Tenon's injection with triamcinolone acetonide levels in experimental undiluted

78 The theoretical model predicted that triamcinolone acetonide levels in systemic blood, vitreo

79 Intravitreal triamcinolone acetonide may be more effective than laser

80 rectomy and ILM peeling assisted with either triamcinolone acetonide or infracyanine green staining i

81 However, triamcinolone acetonide staining is associated with an i

82 Random assignment into 2 groups: 40-mg triamcinolone acetonide subacromial CSI versus 6 session

83 bits received a subconjunctival injection of triamcinolone acetonide to one eye.

84 In summary, the use of inhaled triamcinolone acetonide was associated with loss of BMD

85 Carbon-11-labeled triamcinolone acetonide was formulated as the commercial

86 vehicle and with the vehicle alone, in which triamcinolone acetonide was suspended.

87 ning to glaucoma in response to intravitreal triamcinolone acetonide will be reviewed.

88 the prospective Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in

89 (>/=24 weeks) laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.

90 duction when the R28 cells were treated with triamcinolone acetonide with vehicle (200 microg/mL) for

91 y of ARPE-19 and R28 cells after exposure to triamcinolone acetonide with vehicle 200 microg/mL for 2

92 Triamcinolone acetonide with vehicle caused a greater re

93 ial dehydrogenase activity when treated with triamcinolone acetonide without the vehicle at any of th

94 ons (9453 ranibizumab, 5386 bevacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were rev

95 dophthalmitis per injection was 2 in 935 for triamcinolone acetonide, 3 in 9453 for ranibizumab, and

96 They used inhaled triamcinolone acetonide, 600 mcg, or placebo, twice dail

97 Topical therapy with moderate doses of triamcinolone acetonide, an anti-inflammatory glucocorti

98 corticosteroids (budesonide, dexamethasone, triamcinolone acetonide, and dexamethasone acetate) rang

99 e Flt23k nanoparticles, blank nanoparticles, triamcinolone acetonide, and PBS groups following subcon

100 ant Q642V, which has an altered affinity for triamcinolone acetonide, dexamethasone, and corticostero

101 Four synthetic glucocorticoids (triamcinolone acetonide, fluocinolone acetonide, clobeta

102 e suggested beneficial treatment effects for triamcinolone acetonide, interferon alpha-2a, and supple

103 ne the human biodistribution and kinetics of triamcinolone acetonide, labeled with 11C, formulated an

104 ular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these thera

105 Intravitreal triamcinolone acetonide, pars plana vitrectomy, oral pro

106 Triamcinolone acetonide, the most commonly used intravit

107 in the ARPE-19 cells when treated with both triamcinolone acetonide, with or without the vehicle at

108 he patient underwent periocular injection of triamcinolone acetonide, with resolution of the subretin

109 In contrast, triamcinolone acetonide-induced luciferase activity was

110 uced cataract was observed in 4 intravitreal triamcinolone acetonide-treated patients (12%).

111 sion was documented in 22 (69%) intravitreal triamcinolone acetonide-treated vs 11 (34%) intravitreal

112 ile, and a slightly long-lasting effect than triamcinolone acetonide.

113 a potentiating effect on the cytotoxicity of triamcinolone acetonide.

114 on of xylocaine alone or in combination with triamcinolone acetonide.

115 ns were assessed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (

116 nd frequent intramuscular administrations of triamcinolone achieved control of both the oral and geni

117 d with clobetasol ointment and intralesional triamcinolone, alone or in combination with open superfi

118 Intravitreal triamcinolone also appears to be associated with a reduc

119 sis factor biologic agents, and intravitreal triamcinolone and antivascular endothelial growth factor

120 undergoing cataract surgery, peri-operative triamcinolone and bevacizumab may blunt the progression

121 Adjunctive use of both triamcinolone and bevacizumab with PRP lead to a greater

122 Serum triamcinolone and cortisol levels were inversely correla

123 t, and pegaptanib) and intraocular steroids (triamcinolone and dexamethasone).

124 Intravitreal bevacizumab, intravitreal triamcinolone and laser photocoagulation appear to trans

125 ecently, intraocular corticosteroids such as triamcinolone and steroid-loaded vitreal inserts and imp

126 d- or third-trimester exposure to intranasal triamcinolone and the risk of SGA (OR, 1.06; 95% CI, 0.7

127 end of the run-in, all subjects discontinued triamcinolone and were randomized to continued colchicin

128 Three steroids (betamethasone, triamcinolone, and methylprednisolone) and three local a

129 rative intravitreal bevacizumab, sub-Tenon's triamcinolone, and panretinal photocoagulation (PRP) aft

130 ate steroids cortivazol, methylprednisolone, triamcinolone, and prednisolone.

131 NPV (99.7%-100%) were codes for aflibercept, triamcinolone, and the dexamethasone implant.

132 number of medications, the most common being triamcinolone, antivascular endothelial growth factor (V

133 vs. trial in the in placebo, salmeterol, and triamcinolone arms, respectively.

134 ts With prednisolone, methylprednisolone, or triamcinolone, blood flow was rapidly and completely sto

135 are discussed, as is the use of intravitreal triamcinolone both at the time of cataract surgery and p

136 l injections, and the fact that intravitreal triamcinolone can cause cataract or glaucoma, use of the

137 stent asthma well controlled by low doses of triamcinolone cannot be switched to salmeterol monothera

138 roids (prednisolone, methylprednisolone, and triamcinolone) caused often immediate and complete cessa

139 cortisol suppression: flunisolide-CFC - 936; triamcinolone-CFC - 787; beclomethasone-CFC - 548; fluti

140 red dose inhaler [MDI], flunisolide-CFC, and triamcinolone-CFC), only the placebo group and fluticaso

141 e osteoarthritis, 2 years of intra-articular triamcinolone, compared with intra-articular saline, res

142 Treatment of patients with triamcinolone decreases SDF-1 levels in the vitreous, wi

143 The immunosuppressive effect of triamcinolone does not appear to increase the risk of en

144 salmeterol, a substantial reduction (50%) in triamcinolone dose can occur without a significant loss

145 Maternal exposure to intranasal triamcinolone during pregnancy was not associated with t

146 ss well for patients treated with salmeterol/triamcinolone during the entire study duration, with mid

147 tively, for patients treated with salmeterol/triamcinolone during the first half of the SLIC study an

148 for potential confounders, use of intranasal triamcinolone during the first trimester of pregnancy wa

149 % CI) of treatment failure at the end of the triamcinolone elimination phase in the salmeterol-minus

150 Triamcinolone enhanced iOCT imaging revealed strong vitr

151 , Quebec, Canada, from 1998-2008, intranasal triamcinolone-exposed, other intranasal corticosteroid-e

152 rom a series of 17 treated with intravitreal triamcinolone for retinal vascular disease and diabetes

153 mly assigned to continue both salmeterol and triamcinolone for the remaining 16 weeks (active control

154 l group had more treatment failures than the triamcinolone group (13/54 [24%] vs 3/54 [6%]; P =.004),

155 elated adverse events compared with 5 in the triamcinolone group and had a small increase in hemoglob

156 reatment was not significantly longer in the triamcinolone group than in the salmeterol group.

157 In the triamcinolone group visual acuity showed improved outcom

158 icant differences between the salmeterol and triamcinolone groups were observed for conventional outc

159 r inhibition of IL-4 protein was as follows: triamcinolone > dexamethasone > betamethasone > hydrocor

160 bevacizumab (Avastin) and preservative-free triamcinolone, has significantly expanded our treatment

161 steroid (triamcinolone acetonide [n = 16] or triamcinolone hexacetonide [n = 7]).

162 injection of compounded combined bevacizumab-triamcinolone in a period of 3 weeks had subtle, nonspec

163 mcinolone is better than after orbital floor triamcinolone injection, but that a single intraoperativ

164 limiting membrane peeling, and intravitreal triamcinolone injection.

165 mproved temporarily with sub-Tenon's capsule triamcinolone injections.

166 le intraoperative orbital floor injection of triamcinolone is as effective as a 4-week course of post

167 t in CME and inflammation after intravitreal triamcinolone is better than after orbital floor triamci

168 To compare the efficacy of intravitreal triamcinolone (IVT) and intravitreal bevacizumab (IVB),

169 east as much visual benefit for intravitreal triamcinolone (IVTA) versus laser; (2) a subgroup analys

170 umab (L+B), or focal laser plus intravitreal triamcinolone (L+T) injections.

171 improvements than eyes managed with laser or triamcinolone + laser followed by very deferred ranibizu

172 ser/very deferred ranibizumab (N = 198), and triamcinolone + laser/very deferred ranibizumab (N = 125

173 aser and laser/very deferred ranibizumab and triamcinolone + laser/very deferred ranibizumab was 4.4

174 eau in the range 15 to 25 ng/mL, while serum triamcinolone levels peaked at day 3 near 35 ng/mL and p

175 lly reduced costs, and all treatments except triamcinolone monotherapy increased QALYs.

176 Laser monotherapy and triamcinolone monotherapy were less effective and more c

177 ne plus ibuprofen (n = 10), doxycycline plus triamcinolone (n = 10), or placebo (n = 10).

178 nibizumab (n = 11), bevacizumab (n = 20), or triamcinolone (n = 19).

179 Intra-articular triamcinolone (n = 70) or saline (n = 70) every 12 weeks

180 ies of eyes after intravitreal injections of triamcinolone obtained from a single compounding pharmac

181 yes) who received intravitreal injections of triamcinolone obtained from a single compounding pharmac

182 ed in 82% (14/17) of eyes after intravitreal triamcinolone obtained from the same lot.

183 he combination group compared with 0% in the triamcinolone only group.

184 combination group compared with 47.6% in the triamcinolone-only group and 42.4% in the triamcinolone

185 Laser treatment, intraocular injections of triamcinolone or a vascular endothelial growth factor (V

186 with 130 selective lumbar nerve blocks with triamcinolone or betamethasone.

187 ogists performing intravitreal injections of triamcinolone or other medications of the risk for endop

188 aries per millimeter for methylprednisolone, triamcinolone, or prednisolone, respectively, vs 21.0, 2

189 ofen (P = .03), and 1 given doxycycline plus triamcinolone (P = .14).

190 Experimental vitreous levels of triamcinolone peaked at 111 ng/mL at day 1, then reached

191 he triamcinolone-only group and 42.4% in the triamcinolone plus blank nanoparticle group.

192 ranibizumab plus deferred laser (R+dL), and triamcinolone plus laser (T+L), effectiveness through 10

193 bizumab plus prompt or deferred laser versus triamcinolone plus prompt laser.

194 On day 14, 42% of triamcinolone recipients and 53% of betamethasone recipi

195 t in low back pain (P = .26), whereas 49% of triamcinolone recipients and 55% of betamethasone recipi

196 t in low back pain (P = .38), whereas 52% of triamcinolone recipients and 57% of betamethasone recipi

197 (P = .04, Fisher exact test), whereas 55% of triamcinolone recipients and 57% of betamethasone recipi

198 On day 7, 45% of triamcinolone recipients and 58% of betamethasone recipi

199 On day 3, 42% of triamcinolone recipients and 58% of betamethasone recipi

200 ive nerve root blocks with betamethasone and triamcinolone reduced low back pain and lower extremity

201 Intra-articular triamcinolone resulted in significantly greater cartilag

202 The bevacizumab and triamcinolone results are promising, but the inclusion c

203 dophakic patients, first-line treatment with triamcinolone seems to be the most cost-effective option

204 Triamcinolone staining of the vitreous improves visualiz

205 rations of: dexamethasone (DEX) (0.3 mg/mL), triamcinolone (TA; 0.4-4 mg/mL), or PBS.

206 tal findings demonstrate low levels of serum triamcinolone that alter systemic cortisol levels and hi

207 nanoparticles pre-bound with electro-active triamcinolone, the cortisol level is detected based on i

208 nto: 1) following injections of bevacizumab, triamcinolone, their combination, or ranibizumab regardl

209 Patients were randomly assigned to continue triamcinolone therapy (400 microg twice per day; n = 54)

210 persistent asthma suboptimally controlled by triamcinolone therapy alone but whose asthma symptoms im

211 Patients continued triamcinolone therapy and were randomly assigned to rece

212 However, total elimination of triamcinolone therapy results in a significant deteriora

213 of the salmeterol-minus group 8 weeks after triamcinolone therapy was eliminated compared with 13.7%

214 nd dose-dependent manner, the binding of [3H]triamcinolone to immunoprecipitated GR from mouse L929 f

215 horylation of c-Fos and ERK1/2 were found in triamcinolone-treated mutant retinas.

216 of the salmeterol-minus group 8 weeks after triamcinolone treatment was reduced compared with 2.8% (

217 % (for 8 weeks) then eliminate (for 8 weeks) triamcinolone treatment.

218 We aim to estimate the safety of intranasal triamcinolone use during pregnancy, which was introduced

219 tamer by following signal from the displaced triamcinolone using square wave voltammetry at patterned

220 olled, double-blind trial of intra-articular triamcinolone vs saline for symptomatic knee osteoarthri

221 Pregnancy exposure to intranasal triamcinolone was not significantly associated with the

222 rid treatment and intravitreal injections of triamcinolone, was selected to receive a cycle of three

223 n additional 6 letters correct compared with triamcinolone with laser at an additional cost of $19 21

224 pseudophakics, the ICER value for comparison triamcinolone with laser versus ranibizumab with deferre

225 with deferred laser (P = .001), and 37% with triamcinolone with prompt laser (P = .10).

226 itochondrial dehydrogenase activity than did triamcinolone without vehicle, in both cell lines, altho